• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    6/27/25 7:10:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCRX alert in real time by email
    Form 8-K
    False 0000882796 0000882796 2025-06-27 2025-06-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _________________

    FORM 8-K

    _________________

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):  June 27, 2025

    _______________________________

    BioCryst Pharmaceuticals, Inc.

    (Exact name of registrant as specified in its charter)

    _______________________________

    Delaware 000-23186 62-1413174
    (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

    4505 Emperor Blvd., Suite 200

    Durham, North Carolina 27703

    (Address of Principal Executive Offices) (Zip Code)

    (919) 859-1302

    (Registrant's telephone number, including area code)

     

    (Former name or former address, if changed since last report)

    _______________________________

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock BCRX Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     
     
    Item 8.01. Other Events.

    On June 27, 2025, BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Seller”), issued a press release (the “Press Release”) announcing the execution of a Stock Purchase Agreement, dated as of June 27, 2025, by and among the Seller, BioCryst Ireland Limited, a private limited company incorporated under the laws of Ireland and a wholly owned subsidiary of the Seller (the “Company”), and Neopharmed Gentili S.p.A., a corporation organized under the laws of Italy (the “Purchaser”) (such agreement, the “Purchase Agreement”). The Purchase Agreement provides for the acquisition by the Purchaser of all of the Seller’s equity interests in the Company and its subsidiaries. A copy of the Press Release announcing the execution of the Purchase Agreement is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K, which, in its entirety, is incorporated herein by reference.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit No.   Description
         
    99.1   Press Release of BioCryst Pharmaceuticals, Inc. issued June 27, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    Cautionary Note Regarding Forward-Looking Statements

    This communication includes certain “forward-looking statements” within the meaning of, and subject to the safe harbor created by, the federal securities laws, including statements related to the proposed sale of the Company to the Purchaser (the “Transaction”), including financial estimates and statements as to the expected timing, completion and effects of the Transaction. These forward-looking statements are based on the Seller’s current expectations, estimates and projections regarding, among other things, the expected date of closing of the Transaction and the potential benefits thereof, its business and industry, management’s beliefs and certain assumptions made by the Seller, all of which are subject to change. Forward-looking statements often contain words such as “expect,” “anticipate,” “intend,” “aims,” “plan,” “believe,” “could,” “seek,” “see,” “will,” “may,” “would,” “might,” “considered,” “potential,” “estimate,” “continue,” “likely,” “target” or similar expressions or the negatives of these words or other comparable terminology that convey uncertainty of future events or outcomes. These statements are subject to known and unknown risks, uncertainties, assumptions, estimates, and other important factors that change over time, many of which may be beyond the Seller’s, the Company’s and the Purchaser’s control. The Seller’s future performance and actual results may differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements should not be relied upon as a prediction of actual results. Forward-looking statements include statements regarding, among other things, the benefits of the Transaction, including future financial and operating results and the Seller’s plans, objectives, expectations, intentions, growth strategies and culture and other statements that are not historical facts. Some of the factors that could affect the forward-looking statements contained herein include: (i) the completion of the Transaction on anticipated terms and timing, including obtaining required regulatory approvals, and the satisfaction of other conditions to the completion of the Transaction; (ii) the ability of the Purchaser to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the Transaction; (iii) the risk that disruptions from the Transaction will harm the Seller’s business, including current plans and operations; (iv) the ability of the Seller to retain and hire key personnel; (v) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction; (vi) continued availability of capital and financing and rating agency actions; (vii) legislative, regulatory and economic developments affecting the Seller’s and Company’s businesses; (viii) general economic and market developments and conditions; (ix) potential business uncertainty, including changes to existing business relationships, during the pendency of the Transaction that could affect the Seller’s financial performance; (x) certain restrictions during the pendency of the Transaction that may impact the Seller’s ability to pursue certain business opportunities or strategic transactions; (xi) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism, pandemics, outbreaks of war or hostilities, as well as the Seller’s response to any of the aforementioned factors; (xii) significant transaction costs associated with the Transaction; (xiii) the possibility that the Transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (xiv) the occurrence of any event, change or other circumstance that could give rise to the termination of the Transaction; (xv) competitive responses to the Transaction; and (xvi) the risks and uncertainties pertaining to the Seller’s and the Company’s businesses, including the commercial viability of ORLADEYO and its ability to achieve sustained market acceptance and demand. While the list of factors presented here is considered representative, no such list should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material impact on the Seller’s financial condition, results of operations, credit rating or liquidity. These forward-looking statements speak only as of the date they are made, and the Seller does not undertake to and specifically disclaims any obligation to publicly release the results of any updates or revisions to these forward-looking statements that may be made to reflect future events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

     
     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      BioCryst Pharmaceuticals, Inc.
         
       
    Date: June 27, 2025 By:  /s/ Alane Barnes        
        Alane Barnes
        Chief Legal Officer
       

     

    Get the next $BCRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BCRX

    DatePrice TargetRatingAnalyst
    4/29/2025$20.00Overweight
    Cantor Fitzgerald
    2/25/2025$15.00Outperform
    Wedbush
    11/20/2023$10.00Overweight
    JP Morgan
    9/18/2023$9.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    8/4/2023$11.00Hold → Buy
    Jefferies
    7/13/2023$10.00Neutral → Buy
    BofA Securities
    2/22/2023$14.00Hold → Buy
    Needham
    11/2/2022$14.00 → $16.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $BCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sanders Machelle was granted 12,500 shares, increasing direct ownership by 45% to 40,242 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      6/16/25 4:22:22 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Milano Vincent was granted 12,500 shares, increasing direct ownership by 16% to 89,760 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      6/16/25 4:21:59 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Mckee Amy E was granted 12,500 shares, increasing direct ownership by 45% to 40,331 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      6/16/25 4:21:36 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted eight newly-hired employees restricted stock units (RSUs) covering an aggregate of 57,000 shares of BioCryst common stock. The RSUs were granted as of July 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the compa

      7/3/25 7:00:05 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

      —Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones— —BioCryst plans to use proceeds to retire all remaining term debt, which will eliminate approximately $70 million of future interest payments over remaining life of the loan— —With this transaction, BioCryst expects to end 2027 with approximately $700 million in cash and no term debt (an increase of $400 million from prior 2027 net cash guidance)— RESEARCH TRIANGLE PARK, N.C., June 27, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has entered into a definitive agreement to sell its E

      6/27/25 7:00:12 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

      —Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile— —Patients report improved quality of life and daily functioning with ORLADEYO— RESEARCH TRIANGLE PARK, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data on the long-term efficacy and safety of ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients across all age groups. "These data from both clinical trials and real-world settings continue to strengthen the evidence that ORLADEYO is an effective and well-tolerated long-term p

      6/16/25 7:00:00 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCRX
    SEC Filings

    See more
    • BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

      6/30/25 7:37:57 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

      6/27/25 7:10:00 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

      8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

      6/25/25 6:57:09 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on BioCryst Pharma with a new price target

      Cantor Fitzgerald initiated coverage of BioCryst Pharma with a rating of Overweight and set a new price target of $20.00

      4/29/25 8:10:45 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on BioCryst Pharma with a new price target

      Wedbush initiated coverage of BioCryst Pharma with a rating of Outperform and set a new price target of $15.00

      2/25/25 8:02:33 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan resumed coverage on BioCryst Pharma with a new price target

      JP Morgan resumed coverage of BioCryst Pharma with a rating of Overweight and set a new price target of $10.00

      11/20/23 7:20:41 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Levin Alan G bought $49,996 worth of shares (7,861 units at $6.36), increasing direct ownership by 21% to 44,951 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      5/31/24 4:25:31 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aselage Steve bought $16,000 worth of shares (2,500 units at $6.40) (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      5/29/24 4:16:35 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Hutson Nancy J bought $31,900 worth of shares (5,000 units at $6.38), increasing direct ownership by 6% to 86,818 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      5/22/24 7:24:51 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCRX
    Leadership Updates

    Live Leadership Updates

    See more
    • BioCryst Appoints Steve Frank to Board of Directors

      RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors. Mr. Frank serves as chairman of global healthcare investment banking at J.P. Morgan. He was previously global group head of worldwide healthcare investment banking at Bear Stearns before it was acquired by J.P. Morgan in 2008. Mr. Frank is a trusted corporate advisor, supporting countless transactions including pharmaceutical, biotechnology, medical device and healthcare services firms. A standout institutional investor before becoming a banker, Mr. Frank direct

      5/1/25 7:00:20 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Appoints Dr. Donald Fong Chief Medical Officer

      RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Donald S. Fong, MD, MPH, has been appointed as the company's new chief medical officer, effective immediately. Dr. Fong joins Dr. Helen Thackray, the company's chief research and development officer, and Dr. Bill Sheridan, the company's chief development officer, as physicians on the company's leadership team. "We continue to advance our pipeline of novel therapies to treat diseases with significant unmet needs, including programs in Netherton syndrome and diabetic macular edema that we expect will enter the clinic this year and next year, respectively. Dona

      9/5/24 7:00:00 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

      RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Dr. Nancy Hutson as chair of its board of directors, effective immediately. "I am honored to succeed Bob Ingram. He was a model of effective board leadership for us. Our board is comprised of exceptional people with diverse experience and I am excited to continue working alongside them and the management team to deliver innovative new therapies to patients with rare diseases," said Dr. Hutson. Dr. Hutson was appointed to the board in January 2012, bringing over 30 years of experience as a seasoned professional and leader within the pharmaceutica

      3/31/23 7:00:00 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCRX
    Financials

    Live finance-specific insights

    See more
    • BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

      —Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)— —Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million— —Company now expects to be profitable for full year 2025, a year ahead of schedule— —Company pays down $75 million of debt; saves approximately $23.5 million over life of loan— —NDA submitted for ORLADEYO oral granules for children with HAE aged 2-11— —U.S. IND open for BCX17725 for Netherton syndrome— RESEARCH TRIANGLE PARK, N.C., May 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. "We started 202

      5/5/25 7:00:50 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst to Report First Quarter 2025 Financial Results on May 5

      RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on Monday, May 5, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global b

      4/21/25 7:00:19 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

      —ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)— —FY 2025 ORLADEYO net revenue guidance increased to between $535-$550 million (previously $515-$535 million)— —GAAP operating loss for full year 2024 was $2.5 million; company achieved $62.9 million non-GAAP operating profit in full year 2024 (not including stock-based compensation), expects to approach positive EPS and positive cash flow in 2H 2025— —Initial clinical data from BCX17725 in Netherton syndrome and avoralstat in diabetic macular edema targeted by end of year— —Company expects to expand ORLADEYO label to children with HAE aged 2 to 11 using oral gra

      2/24/25 7:00:48 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

      SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

      11/7/24 10:52:17 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

      SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

      11/7/24 10:25:46 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

      SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

      11/4/24 11:18:36 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care